Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01940900
Registration number
NCT01940900
Ethics application status
Date submitted
9/09/2013
Date registered
12/09/2013
Titles & IDs
Public title
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Query!
Scientific title
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.
Query!
Secondary ID [1]
0
0
OPH1003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Age-Related Macular Degeneration
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - E10030 sham intravitreal injection
Experimental: E10030 + ranibizumab - E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
Active comparator: Sham + ranibizumab - E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
Treatment: Drugs: E10030 sham intravitreal injection
Pressure on the eye with a syringe with no needle
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Change in Visual Acuity From Baseline to 12 Months
Query!
Assessment method [1]
0
0
The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline to the month 12 visit. Higher ETDRS letters represents higher vision and a higher change in ETDRS letters represents better functioning.
Query!
Timepoint [1]
0
0
12 Months
Query!
Eligibility
Key inclusion criteria
* Subjects of either gender aged = 50 years
* Active subfoveal choroidal neovascularization (CNV) secondary to AMD
* Presence of sub-retinal hyper-reflective material (SD-OCT)
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral supplements of vitamins and minerals
* Any prior intravitreal treatment in the study eye prior to the Day 1 visit, regardless of indication (including intravitreal corticosteroids)
* Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication
* Subjects with subfoveal scar or subfoveal atrophy are excluded
* Diabetes mellitus
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
627
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- East Melbourne
Query!
Recruitment hospital [2]
0
0
- Malvern
Query!
Recruitment hospital [3]
0
0
- Nedlands
Query!
Recruitment hospital [4]
0
0
- Parramatta
Query!
Recruitment hospital [5]
0
0
- Sydney
Query!
Recruitment hospital [6]
0
0
- Westmead
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [3]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [4]
0
0
2150 - Parramatta
Query!
Recruitment postcode(s) [5]
0
0
2000 - Sydney
Query!
Recruitment postcode(s) [6]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oklahoma
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Dakota
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Tennessee
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Utah
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Buenos Aires
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Cordoba
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Santa Fe
Query!
Country [27]
0
0
Colombia
Query!
State/province [27]
0
0
Bogota
Query!
Country [28]
0
0
Colombia
Query!
State/province [28]
0
0
Cali
Query!
Country [29]
0
0
Colombia
Query!
State/province [29]
0
0
Medellin
Query!
Country [30]
0
0
Denmark
Query!
State/province [30]
0
0
Aalborg
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Aarhus C
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Glostrup
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Odense
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
Roskilde
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Créteil
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Lyon
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Marseille
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Paris
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rouen
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Strasbourg
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Tours
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Aachen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Bonn
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Freiburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Göttingen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Hamburg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Heidelberg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Karlsruhe
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Kiel
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Köln
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Leipzig
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Luebeck
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Mainz
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Muenchen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Muenster
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
München
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Münster
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Tübingen
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Budapest
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Debrecen
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Magyarszék
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Pecs
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Szeged
Query!
Country [64]
0
0
Israel
Query!
State/province [64]
0
0
Haifa
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Jerusalem
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Kfar-Saba
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Petah Tikva
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Rehovot
Query!
Country [69]
0
0
Israel
Query!
State/province [69]
0
0
Tel Aviv
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Barcelona
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Bilbao
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Las Palmas
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Navarro
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Sant Cugat Del Vallès
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Valencia
Query!
Country [76]
0
0
Turkey
Query!
State/province [76]
0
0
Ankara
Query!
Country [77]
0
0
Turkey
Query!
State/province [77]
0
0
Izmir
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Ophthotech Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Query!
Trial website
https://clinicaltrials.gov/study/NCT01940900
Query!
Trial related presentations / publications
Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019 Jun;24(2):107-119. doi: 10.1080/14728214.2019.1604684. Epub 2019 Apr 19.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
There is no plan to share individual participant data at this time
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01940900